NYSE: BTI$ 65.18(-2.279)
Our purpose is clear: Build A Better Tomorrow™.
Tobacco products exist on a continuum of risk to the consumer’s health, with combustible cigarettes being the riskiest.
At Reynolds, we put science first, focusing our nicotine and tobacco science research and technology efforts on potentially reduced-risk products as we accelerate our Tobacco Harm Reduction efforts to reduce the health impact of our business.
We operate in a broad spectrum of scientific fields including molecular biology, toxicology, and chemistry as we assess the reduced-risk potential of our products. It is essential that these products are backed by strong science and that science is peer-reviewed by the scientific community.
We are building the foundation for non-combustible products through robust science, including our 9-Step Framework to assess the risk of our products. Our framework includes scientific studies starting from small-scale studies at the laboratory bench all the way up to large-scale studies examining the effect of our products on public health.
For more in-depth information on our science please visit:
In response to FDA’s open public comment period in March of 2026 regarding Draft Guidance on Applications for Flavored E-Cigarettes, Reynolds American submitted the following comment: Re: Docket No. FDA-2026-D-1817 (91 Fed. Reg. 11980, Mar. 11, 2026) – “Flavored Electronic Nicotine Delivery Systems (ENDS) Premarket Applications—Considerations Related to Youth Risk” RAI Services Company … Continued
Reynolds American recently partnered with SEMAFOR to highlight the launch of a forward-looking $3.2 billion investment to progress toward a Smokeless America. For more than 150 years, the Reynolds American organization has been an enduring part of American industry. Today, the organization continues to invest in the communities where employees live and work, train … Continued
The Reynolds American organization (Reynolds) has partnered with Custom Content from WSJ to highlight how the organization is defining its next era following its 150th anniversary last year. The feature explores how Reynolds is navigating one of the most significant evolutions in its history, transitioning from a combustible-products business toward a predominantly smokeless trajectory … Continued
Our team of world-class researchers and scientists provided robust evidence throughout the year to support our New Category products in THR. In 2023 alone, we produced 19 publications and 35 key presentations.
The key themes across these publications were THR and strengthening scientific positions for alternative products. Conferences attended by our team included the Food & Drug Law Institute Tobacco and Nicotine Product Regulatory Science Symposium, Next Generation Nicotine Delivery, and the Cooperation Centre for Scientific Research Relative to Tobacco.